Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 10/23 10:00:00 pm
122.37 USD   +0.86%
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVE : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
10/23Celgene Corporation initiated by Guggenheim at buy.  
10/23Top Celgene cancer drugs now 20% more expensive after latest price hikes: The.. 
10/23LOL, just now on CNBC: "Final Trade?" "Microsoft" "Cisco Systems" "Nvidia" ..
13
10/23$IBB sitting on the 50 Day MA with $AMGN, $GILD and $CELG reporting earnings ..
15
10/23My Latest: Celgene Shocker Could End Biotech Rally $CELG $IBB
1
10/23On The Fly: Top five analyst downgrades $GE $STI $CELG $FL $BIIB  
10/23$CELG Morgan Stanley reiterates Underweight. PT lowered to $115
2
10/23Celgene Corporation's PT cut by Morgan Stanley to $115.00. underweight rating.. 
10/23$CELG Revlimid price history, per SunTrust. Nearly doubled in 7 yrs
10
10/23Celgene Corporation $CELG Earns Buy Rating from Wells Fargo & Company  
10/23In today's drug price increases, $CELG hikes Revlimid by 9% (3rd increase thi..
22
10/23Stifel Nicolaus Cuts Celgene Corporation $CELG Price Target to $149.00  
10/23Celgene Corporation (NASDAQ:CELG) #Stocks to Watch: Celgene Corporation (NASD..
1
10/23Celgene Corporation's neutral rating reiterated at Piper Jaffray Companies. $.. 
10/23Celgene (CELG) Sank To A 4-Month Low After Crohn's Disease Treatment Abandone.. 
10/2335 Biggest Movers From Friday
3
10/23What's next for #biopharma Q3 earnings
1
10/23$CELG downgraded to Neutral from Overweight at Piper. PT $133 from $145
1
10/23Celgene Corporation $CELG Holdings Lifted by Global Thematic Partners LLC  
10/23Celgene Corporation upgraded by Vetr Inc. to strong-buy. $144.39 PT.  
10/23On the other hand $CELG and $CJR.B most oversold. Trading bounce? 
10/23ICYMI my VIDEO
4
10/22Celgene Corporation's hold rating reiterated at BTIG Research.  
10/22BTIG Releases a Hold Rating on Celgene $CELG  
10/22$CELG - Celgene Corporation #CELG Stock Rating Lowered by Citigroup Inc.  
10/22Celgene Corporation $CELG Stock Rating Lowered by Citigroup Inc.  
10/22Celgene's selloff today is just a little bit overdone  
10/22Traders Buy Shares of Celgene Corporation $CELG on Weakness Following Analyst.. 
10/22Celgene Corporation $CELG Price Target Cut to $146.00 by Analysts at UBS AG  
10/22$CELG - Celgene Corporation #CELG Price Target Cut to $146.00 by Analysts at .. 
10/21Celgene Corporation $CELG Downgraded by Zacks Investment Research  
10/21$CELG Information for Celgene Corporation From our Stock News Alerts App 
10/21How Big of a Deal Is Celgene's Flop?: Motley Fool  
10/21Somerset Group LLC Continues to Hold Holdings in Celgene Corporation $CELG  
10/21Celgene Corporation $CELG is Edinburgh Partners Ltd’s 3rd Largest Position  
10/21Unusual option activity alert: $CELG 10x average daily volume, $CZR 9x, $IPG .. 
10/20In honor of the World Series next week, the traders give their home run stock..
5
10/20Celgene is our most-clicked stock of the day. Here's why:
8
10/20The Biggest Loser: Does Celgene Need to Pipe Up?  
10/20On The Fly: Top stock stories for Friday $GE $PG $CELG $SNCR $IL $SKX $PYPL $..
9
10/20Watch Us Report LIVE from the Floor of the NYSE! This weeks weekly wrap-up in.. 
10/20Watch Us Report LIVE from the Floor of the NYSE! This weeks weekly wrap-up in.. 
10/20VIDEO
18
10/20$CELG lost 1 Kite Pharma in value today.
8
10/20$CELG -11% heading into the close. Is that $11-12B in market value erased? ..
3
10/20Top story -- UPDATED: Celgene’s $710M deal on mongersen implodes as Phase III..
4
10/20Celgene's selloff today is just a little bit overdone  
10/20#gold #price GoldMarketNews.EU Celgene Could Be the Best CAR-T Stock to Buy, .. 
10/20it pays to track your stuff on a Weekly, that $CELG 'dbl triangle' candle wk ..
1
10/20[email protected] abandons Crohn's drug trials, shares drop  
10/20$CELG Weekly VZSPECIALEDITION nice run in Sep, then had rare "dbl triangle" ..
1
10/2032 Stocks Moving In Friday's Mid-Day Session  
10/20#StupidStock Move of the Day! Celgene discontinuing its Crohn's disease drug .. 
10/20Drug That Celgene Bought For $710 Million Fails via @forbes  
10/20We never like to see this, but it DOES happen $CELG
2
10/20The Ratings Game: Celgene dives 10% after ditching key drug: The once high-pr.. 
10/20$CELG this is a failed setup where there was no graceful exit...and very big ..
3
10/20Celgene: No Surprise? It's 10% Drop Says Otherwise
1
10/20The drug for Crohn's disease that Celgene bought for $710 million has failed ..
22
10/20Celgene Corporation's outperform rating reiterated at William Blair.  
10/202020 guidance works… until it doesn’t. $CELG
1
10/20Celgene: No Surprise? It?s 10% Drop Says Different.  
10/20$CELG down 10% on mongersen miss. Analysts debate buying opp vs poor decision..
1
10/20On The Fly: Top five analyst downgrades $PHM $CELG $HPE $REGN $BOJA  
10/20Biotech giant Celgene is abandoning a drug it bought for $710 million  
10/20Biotech giant Celgene is abandoning a drug it bought for $710 million  
10/20Biotech giant Celgene is abandoning a drug it bought for $710 million
4
10/20$CELG is falling hard after testing the YearlyR2 Pivots. My target is the Yea.. 
10/20Biotech giant Celgene is abandoning a drug it bought for $710 million  
10/20Biotech giant Celgene is abandoning a drug it bought for $710 million  
Next »
Qtime:697
Financials ($)
Sales 2017 13 226 M
EBIT 2017 7 429 M
Net income 2017 4 475 M
Debt 2017 3 949 M
Yield 2017 -
P/E ratio 2017 22,00
P/E ratio 2018 16,80
EV / Sales 2017 7,54x
EV / Sales 2018 6,14x
Capitalization 95 736 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 148 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION5.72%95 736
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223